Literature DB >> 8673758

Changes in coronary sinus pH during dipyridamole stress in patients with hypertrophic cardiomyopathy.

P M Elliott1, G M Rosano, J S Gill, P A Poole-Wilson, J C Kaski, W J McKenna.   

Abstract

OBJECTIVES: The presence of angina pectoris and myocardial scarring in patients with hypertrophic cardiomyopathy (HCM) suggests that myocardial ischemia is a factor in the pathophysiology of the disease. The clinical evaluation of ischaemia is problematic in HCM as baseline electrocardiographic abnormalities are frequent and thallium-201 perfusion abnormalities correlate poorly with anginal symptoms. Coronary sinus pH measurement using a catheter mounted pH electrode is a validated sensitive technique for the detection of myocardial ischaemia. METHODS AND
RESULTS: 11 patients with HCM and chest pain (eight men; mean (SD) (range) age 36 (11) (19-53) years) and six controls (two men; mean (SD) (range) age 49 (11) (31-62) years) with atypical pain and normal coronary angiograms were studied. Eight patients with HCM had baseline ST segment depression of > or = 1 mm and four had reversible perfusion defects during stress 201TI scintigraphy. A catheter mounted hydrogen ion sensitive electrode was introduced into the coronary sinus and pH monitored continuously during dipyridamole infusion (0.56 mg/kg over four min). The maximal change in coronary sinus pH during dipyridamole stress was greater in patients with HCM than in controls (0.082 (0.083) (0 to -0.275) v 0.005 (0.006) (0 to -0.012), P = 0.02). In six patients (four men; mean (SD) (range) age 29 (9) (19-40 years) the development of chest pain was associated with a gradual decline in coronary sinus pH (mean 0.123 (0.089)), peaking at 442 (106) s. There were no relations among left ventricular dimensions, maximal wall thickness, and maximum pH change. In patients with HCM there was a correlation between maximum pH change and maximum heart rate during dipyridamole infusion (r = 0.70, P = 0.02).
CONCLUSION: This study provides further evidence that chest pain in patients with HCM is caused by myocardial ischaemia. The role of myocardial ischaemia in the pathophysiology of the disease remains to be determined but coronary sinus pH monitoring provides a method for quantifying and prospectively assessing its effects on clinical presentation and prognosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8673758      PMCID: PMC484256          DOI: 10.1136/hrt.75.2.179

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  25 in total

1.  A critical appraisal of the electrocardiographic criteria for the diagnosis of left ventricular hypertrophy.

Authors:  D W Romhilt; K E Bove; R J Norris; E Conyers; S Conradi; D T Rowlands; R C Scott
Journal:  Circulation       Date:  1969-08       Impact factor: 29.690

2.  Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history.

Authors:  S Frank; E Braunwald
Journal:  Circulation       Date:  1968-05       Impact factor: 29.690

3.  Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. I. Physiologic basis and experimental validation.

Authors:  K L Gould
Journal:  Am J Cardiol       Date:  1978-02       Impact factor: 2.778

4.  Regional thallium-201 washout and myocardial hypertrophy in hypertrophic cardiomyopathy and its relation to exertional chest pain.

Authors:  J Takata; P J Counihan; J N Gane; Y Doi; T Chikamori; T Ozawa; W J McKenna
Journal:  Am J Cardiol       Date:  1993-07-15       Impact factor: 2.778

5.  Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries.

Authors:  A Pasternac; J Noble; Y Streulens; R Elie; C Henschke; M G Bourassa
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

6.  Idiopathic hypertrophic subaortic stenosis: evaluation of anginal symptoms with thallium-201 myocardial imaging.

Authors:  K A Rubin; J Morrison; M B Padnick; A J Binder; S Chiaramida; D Margouleff; V T Padmanabhan; S J Gulotta
Journal:  Am J Cardiol       Date:  1979-11       Impact factor: 2.778

7.  Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study.

Authors:  L M Shapiro; W J McKenna
Journal:  J Am Coll Cardiol       Date:  1983-09       Impact factor: 24.094

8.  Myocardial lactate extraction: multi-determined metabolic function.

Authors:  E W Gertz; J A Wisneski; R Neese; A Houser; R Korte; J D Bristow
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

9.  Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy.

Authors:  W J Stafford; R G Trohman; M Bilsker; L Zaman; A Castellanos; R J Myerburg
Journal:  J Am Coll Cardiol       Date:  1986-03       Impact factor: 24.094

10.  Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures.

Authors:  R O Cannon; D R Rosing; B J Maron; M B Leon; R O Bonow; R M Watson; S E Epstein
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

View more
  7 in total

1.  Natural history of hypertrophic cardiomyopathy.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 2.  The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

3.  Do myocardial perfusion SPECT and radionuclide angiography studies in adult patients with hypertrophic cardiomyopathy have prognostic implications?

Authors:  Guillermo Romero-Farina; Jaume Candell-Riera; Enrique Galve; Lluís Armadans; Francisca Ramos; Joan Castell; Santiago Aguadé; Juan M Nogales; Jordi Soler-Soler
Journal:  J Nucl Cardiol       Date:  2004 Sep-Oct       Impact factor: 5.952

4.  Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy.

Authors:  S Jones; P M Elliott; S Sharma; W J McKenna; B J Whipp
Journal:  Heart       Date:  1998-07       Impact factor: 5.994

5.  Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.

Authors:  P M Elliott; H Kindler; J S Shah; B Sachdev; O E Rimoldi; R Thaman; M T Tome; W J McKenna; P Lee; P G Camici
Journal:  Heart       Date:  2005-08-05       Impact factor: 5.994

6.  Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance.

Authors:  Claire E Raphael; Robert Cooper; Kim H Parker; Julian Collinson; Vassilis Vassiliou; Dudley J Pennell; Ranil de Silva; Li Yueh Hsu; Anders M Greve; Sukh Nijjer; Chris Broyd; Aamir Ali; Jennifer Keegan; Darrel P Francis; Justin E Davies; Alun D Hughes; Andrew Arai; Michael Frenneaux; Rod H Stables; Carlo Di Mario; Sanjay K Prasad
Journal:  J Am Coll Cardiol       Date:  2016-10-11       Impact factor: 24.094

Review 7.  Deciphering hypertrophic cardiomyopathy with electrocardiography.

Authors:  Thomas Gossios; Konstantinos Savvatis; Thomas Zegkos; Dimitrios Ntelios; Pavlos Rouskas; Despoina Parcharidou; Haralambos Karvounis; Georgios K Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-07-21       Impact factor: 4.654

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.